€118.00
Product information
| Active substances | POLYNUCLEOTIDE ( PN-HPT HIGHLY PURIFIED POLYNUCLEOTIDE TECHNOLOGY) |
|---|---|
| Manufacturer | Croma |
| Pack size | 1 x 2ml Pre-Filled Syringe |
| Strength | 40mg/2ml |
We guarantee your order will arrive quickly. Most parcels are delivered within 5–10 business days, ensuring you get the products you need when you need them.
Enjoy personalized support with a dedicated account manager. From product selection to tracking, you’ll always have a trusted partner by your side.
Shop confidently from our selection of medical products. Each item is available for fast, reliable delivery, so your practice stays fully stocked.
We supply only authentic products, backed by full traceability. Every order comes with confidence, transparency, and assurance of verified sourcing.
CROMA PhilArt is an advanced polynucleotide-based injectable solution designed for comprehensive skin regeneration. This innovative dermal filler treatment utilizes biocompatible DNA fragments to stimulate cellular repair mechanisms, promoting natural collagen synthesis and tissue revitalization. CROMA PhilArt offers targeted therapeutic benefits for multiple anatomical regions, delivering clinical-grade results for aesthetic applications.
The product formulation incorporates high-molecular-weight polynucleotides that enhance fibroblast activity, improve tissue hydration, and support skin structural integrity. This approach distinguishes CROMA from traditional fillers, focusing on intrinsic skin quality improvement rather than superficial augmentation.
Professional administration requires specific technical protocols for optimal therapeutic outcomes. Standard treatment involves microinjection techniques utilizing fine needles or cannula methods, depending on anatomical location and clinical objectives.
Recommended dosage varies according to treatment area, with facial applications requiring 2–3ml per session. The PhilArt EYE variant utilizes smaller volumes with superficial injection techniques. Treatment intervals generally span 2–3 weeks for initial protocols, with maintenance sessions scheduled according to patient response.
The active pharmaceutical component comprises purified polynucleotides derived from salmon DNA, processed through proprietary extraction methods. These hyaluronic acid-free formulations eliminate allergenicity concerns while maintaining biocompatibility across diverse patient populations.
Supporting ingredients include physiological saline solution and stabilizing components, maintaining product integrity. The formulation excludes lidocaine and other anesthetic agents, requiring separate numbing protocols when necessary.
Proper storage after purchase of CROMA products maintains their stability and therapeutic efficacy. CROMA PhilArt requires refrigerated storage between 2-8°C, protected from direct light exposure and temperature fluctuations. Practitioners should implement cold chain management protocols during transportation. Avoid freezing temperatures. Unopened vials maintain stability for 24 months under appropriate conditions.
Absolute contraindications include:
Relative contraindications encompass:
Comprehensive medical history reviews and physical examinations are essential before treatment approval.
Professional administration by qualified medical practitioners represents an essential safety requirement. Practitioners should maintain current training in injection techniques and emergency management protocols.
Patient selection requires careful medical history consideration, current medications assessment, and realistic expectation evaluation. Avoid treatment in areas with active inflammation, recent trauma, or compromised tissue integrity.
CROMA-PHARMA GmbH manufactures CROMA PhilArt under ISO 13485 quality management standards and CE marking compliance. The product meets Medical Device Regulation requirements for Class III injectable devices.
Regulatory approval encompasses multiple international markets, with specific registration requirements varying by jurisdiction. Practitioners should verify local regulatory status and maintain appropriate documentation for professional use.
